Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Discover Oncology
Published in: Discover Oncology 1/2023

Open Access 01-12-2023 | Prostate Cancer | Review

Molecular pathogenesis, mechanism and therapy of Cav1 in prostate cancer

Authors: Qiang Bian, Bei Li, Luting Zhang, Yinuo Sun, Zhankui Zhao, Yi Ding, Honglian Yu

Published in: Discover Oncology | Issue 1/2023

Login to get access

Abstract

Prostate cancer is the second incidence of malignant tumors in men worldwide. Its incidence and mortality are increasing year by year. Enhanced expression of Cav1 in prostate cancer has been linked to both proliferation and metastasis of cancer cells, influencing disease progression. Dysregulation of the Cav1 gene shows a notable association with prostate cancer. Nevertheless, there is no systematic review to report about molecular signal mechanism of Cav1 and drug treatment in prostate cancer. This article reviews the structure, physiological and pathological functions of Cav1, the pathogenic signaling pathways involved in prostate cancer, and the current drug treatment of prostate cancer. Cav1 mainly affects the occurrence of prostate cancer through AKT/mTOR, H-RAS/PLCε, CD147/MMPs and other pathways, as well as substance metabolism including lipid metabolism and aerobic glycolysis. Baicalein, simvastatin, triptolide and other drugs can effectively inhibit the growth of prostate cancer. As a biomarker of prostate cancer, Cav1 may provide a potential therapeutic target for the treatment of prostate cancer.
Literature
1.
Wong ECL, Kapoor A. Epidemiology of prostate and kidney cancer in the Aboriginal population of Canada: A systematic review. Can Urol Assoc J. 2017;11(5):E222–32.PubMedPubMedCentralCrossRef
2.
Trama A, Botta L, Nicolai N, Rossi PG, Contiero P, Fusco M, et al. Prostate cancer changes in clinical presentation and treatments in two decades: an Italian population-based study. Eur J Cancer. 2016;67:91–8.PubMedCrossRef
3.
Kamibeppu T, Yamasaki K, Nakahara K, Nagai T, Terada N, Tsukino H, et al. Caveolin-1 and -2 regulate cell motility in castration-resistant prostate cancer. Res Rep Urol. 2018;10:135–44.PubMedPubMedCentral
4.
Swami U, McFarland TR, Nussenzveig R, Agarwal N. Advanced prostate cancer: treatment advances and future directions. Trends in Cancer. 2020;6(8):702–15.PubMedCrossRef
5.
Achard V, Putora PM, Omlin A, Zilli T, Fischer S. Metastatic prostate cancer: treatment options. Oncology. 2022;100(1):48–59.PubMedCrossRef
6.
7.
Terada N, Akamatsu S, Kobayashi T, Inoue T, Ogawa O, Antonarakis ES. Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Ther Adv Med Oncol. 2017;9(8):565–73.PubMedPubMedCentralCrossRef
8.
Engelman JA, Zhang XL, Lisanti MP. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett. 1998;436(3):403–10.PubMedCrossRef
9.
Jenkins R, Takahashi S, DeLacey K, Bergstralh E, Lieber M. Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer. Genes Chromosomes Cancer. 1998;21(2):131–43.PubMedCrossRef
10.
Nassar ZD, Hill MM, Parton RG, Francois M, Parat MO. Non-caveolar caveolin-1 expression in prostate cancer cells promotes lymphangiogenesis. Oncoscience. 2015;2(7):635–45.PubMedPubMedCentralCrossRef
11.
Ayala G, Morello M, Frolov A, You S, Li R, Rosati F, et al. Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. J Pathol. 2013;231(1):77–87.PubMedPubMedCentralCrossRef
12.
Thompson TC, Tahir SA, Li L, Watanabe M, Naruishi K, Yang G, et al. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis. 2009;13(1):6–11.PubMedPubMedCentralCrossRef
13.
Guo Z, Hu X, Xing Z, Xing R, Lv R, Cheng X, et al. Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway. Mol Cell Biochem. 2015;406(1–2):111–9.PubMedPubMedCentralCrossRef
14.
Gao Y, Li L, Li T, Ma L, Yuan M, Sun W, et al. Simvastatin delays castration-resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin-1. Int J Oncol. 2019;54(6):2054–68.PubMedPubMedCentral
15.
Yuan S, Wang L, Chen X, Fan B, Yuan Q, Zhang H, et al. Triptolide inhibits the migration and invasion of human prostate cancer cells via Caveolin-1/CD147/MMPs pathway. Biomed Pharmacother. 2016;84:1776–82.PubMedCrossRef
16.
Goh M, Chen F, Paulsen MT, Yeager AM, Dyer ES, Ljungman M. Phenylbutyrate attenuates the expression of Bcl-X (L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells. Neoplasia. 2001;3(4):331–8.PubMedPubMedCentralCrossRef
17.
Iguchi K, Matsunaga S, Nakano T, Usui S, Hirano K. Inhibition of caveolin-1 expression by incadronate in PC-3 prostate cells. Anticancer Res. 2006;26(4B):2977–81.PubMed
18.
Ifere GO, Equan A, Gordon K, Nagappan P, Igietseme JU, Ananaba GA. Cholesterol and phytosterols differentially regulate the expression of caveolin 1 and a downstream prostate cell growth-suppressor gene. Cancer Epidemiol. 2010;34(4):461–71.PubMedPubMedCentralCrossRef
19.
20.
21.
Scherer PE, Okamoto T, Chun M, Nishimoto I, Lodish HF, Lisanti MP. Identification, sequence, and expression of caveolin-2 defines a caveolin gene family. Proc Natl Acad Sci USA. 1996;93(1):131–5.PubMedPubMedCentralCrossRef
22.
23.
Sonnino S, Prinetti A. Sphingolipids and membrane environments for caveolin. FEBS Lett. 2009;583(4):597–606.PubMedCrossRef
24.
Wu HC, Chang CH, Tsou YA, Tsai CW, Lin CC, Bau DT. Significant association of caveolin-1 (CAV1) genotypes with prostate cancer susceptibility in Taiwan. Anticancer Res. 2011;31(2):745–9.PubMed
25.
Bennett N, Hooper JD, Lee CS, Gobe GC. Androgen receptor and caveolin-1 in prostate cancer. IUBMB Life. 2009;61(10):961–70.PubMedCrossRef
26.
Song KS, Tang Z, Li S, Lisanti MP. Mutational analysis of the properties of caveolin-1. A novel role for the C-terminal domain in mediating homo-typic caveolin-caveolin interactions. J Biol Chem. 1997;272(7):4398–403.PubMedCrossRef
27.
Sargiacomo M, Scherer PE, Tang Z, Kubler E, Song KS, Sanders MC, et al. Oligomeric structure of caveolin: implications for caveolae membrane organization. Proc Natl Acad Sci USA. 1995;92(20):9407–11.PubMedPubMedCentralCrossRef
28.
Schlegel A, Schwab RB, Scherer PE, Lisanti MP. A role for the caveolin scaffolding domain in mediating the membrane attachment of caveolin-1. The caveolin scaffolding domain is both necessary and sufficient for membrane binding in vitro. J Biol Chem. 1999;274(32):22660–7.PubMedCrossRef
29.
Woodman SE, Schlegel A, Cohen AW, Lisanti MP. Mutational analysis identifies a short atypical membrane attachment sequence (KYWFYR) within caveolin-1. Biochemistry. 2002;41(11):3790–5.PubMedCrossRef
30.
Wong TH, Dickson FH, Timmins LR, Nabi IR. Tyrosine phosphorylation of tumor cell caveolin-1: impact on cancer progression. Cancer Metastasis Rev. 2020;39(2):455–69.PubMedCrossRef
31.
Bernatchez P. Endothelial caveolin and its scaffolding domain in cancer. Cancer Metastasis Rev. 2020;39(2):471–83.PubMedCrossRef
32.
Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol. 2012;7:423–67.PubMedCrossRef
33.
Ketteler J, Klein D. Caveolin-1, cancer and therapy resistance. Int J Cancer. 2018;143(9):2092–104.PubMedCrossRef
34.
Okamoto T, Schlegel A, Scherer PE, Lisanti MP. Caveolins, a family of scaffolding proteins for organizing “preassembled signaling complexes” at the plasma membrane. J Biol Chem. 1998;273(10):5419–22.PubMedCrossRef
35.
Kogo H, Aiba T, Fujimoto T. Cell type-specific occurrence of caveolin-1alpha and -1beta in the lung caused by expression of distinct mRNAs. J Biol Chem. 2004;279(24):25574–81.PubMedCrossRef
36.
Shajahan AN, Dobbin ZC, Hickman FE, Dakshanamurthy S, Clarke R. Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK). J Biol Chem. 2012;287(21):17682–92.PubMedPubMedCentralCrossRef
37.
Quest AF, Lobos-Gonzalez L, Nunez S, Sanhueza C, Fernandez JG, Aguirre A, et al. The caveolin-1 connection to cell death and survival. Curr Mol Med. 2013;13(2):266–81.PubMedCrossRef
38.
Chang CC, Chen CY, Wen HC, Huang CY, Hung MS, Lu HC, et al. Caveolin-1 secreted from adipose tissues and adipocytes functions as an adipogenesis enhancer. Obesity. 2017;25(11):1932–40.PubMedCrossRef
39.
Panic A, Ketteler J, Reis H, Sak A, Herskind C, Maier P, et al. Progression-related loss of stromal Caveolin 1 levels fosters the growth of human PC3 xenografts and mediates radiation resistance. Sci Rep. 2017;7:41138.PubMedPubMedCentralCrossRef
40.
Sternberg PW, Schmid SL. Caveolin, cholesterol and Ras signalling. Nat Cell Biol. 1999;1(2):E35–7.PubMedCrossRef
41.
Sugie S, Tsukino H, Yamauchi T, Mukai S, Fujii M, Shibata N, et al. Functional polymorphism in the CAV1 T29107A gene and its association with prostate cancer risk among Japanese men. Anticancer Res. 2013;33(3):1023–7.PubMed
42.
Corn PG, Thompson TC. Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit. Cancer Manag Res. 2010;2:111–22.PubMedPubMedCentralCrossRef
43.
Yang G, Goltsov AA, Ren C, Kurosaka S, Edamura K, Logothetis R, et al. Caveolin-1 upregulation contributes to c-Myc–induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res. 2012;10(2):218–29.PubMedCrossRef
44.
Carver LA, Schnitzer JE. Caveolae: mining little caves for new cancer targets. Nat Rev Cancer. 2003;3(8):571–81.PubMedCrossRef
45.
Massimino ML, Griffoni C, Spisni E, Toni M, Tomasi V. Involvement of caveolae and caveolae-like domains in signalling, cell survival and angiogenesis. Cell Signal. 2002;14(2):93–8.PubMedCrossRef
46.
Frank PG, Woodman SE, Park DS, Lisanti MP. Caveolin, caveolae, and endothelial cell function. Arterioscler Thromb Vasc Biol. 2003;23(7):1161–8.PubMedCrossRef
47.
Ng L, Wong SK, Huang Z, Lam CS, Chow AK, Foo DC, et al. CD26 induces colorectal cancer angiogenesis and metastasis through CAV1/MMP1 signaling. Int J Mol Sci. 2022;23(3):1181.PubMedPubMedCentralCrossRef
48.
Shi F, Chen X, Wang Y, Xie Y, Zhong J, Su K, et al. HOTAIR/miR-203/CAV1 crosstalk influences proliferation, migration, and invasion in the breast cancer cell. Int J Mol Sci. 2022;23(19):11755.PubMedPubMedCentralCrossRef
49.
Linge A, Weinhold K, Blasche R, Kasper M, Barth K. Downregulation of caveolin-1 affects bleomycin-induced growth arrest and cellular senescence in A549 cells. Int J Biochem Cell Biol. 2007;39(10):1964–74.PubMedCrossRef
50.
Yu Q. Restoring p53-mediated apoptosis in cancer cells: new opportunities for cancer therapy. Drug Resist Updat. 2006;9(1–2):19–25.PubMedCrossRef
51.
52.
Zhou W, He L, Dai Y, Zhang Y, Wang J, Liu B. MicroRNA-124 inhibits cell proliferation, invasion and migration by targeting CAV1 in bladder cancer. Exp Ther Med. 2022;23(4):312.PubMedPubMedCentralCrossRef
53.
Raja SA, Shah STA, Tariq A, Bibi N, Sughra K, Yousuf A, et al. Caveolin-1 and dynamin-2 overexpression is associated with the progression of bladder cancer. Oncol Lett. 2019;18(1):219–26.PubMedPubMedCentral
54.
Liu B, Zhang J, Yang D. miR-96-5p promotes the proliferation and migration of ovarian cancer cells by suppressing Caveolae1. J Ovarian Res. 2019;12(1):57.PubMedPubMedCentralCrossRef
55.
56.
Leiser D, Samanta S, Eley J, Strauss J, Creed M, Kingsbury T, et al. Role of caveolin-1 as a biomarker for radiation resistance and tumor aggression in lung cancer. PLoS ONE. 2021;16(11): e0258951.PubMedPubMedCentralCrossRef
57.
Shi YB, Li J, Lai XN, Jiang R, Zhao RC, Xiong LX. Multifaceted roles of Caveolin-1 in lung cancer: a new investigation focused on tumor occurrence, development and therapy. Cancers. 2020;12(2):291.PubMedPubMedCentralCrossRef
58.
Ariotti N, Wu Y, Okano S, Gambin Y, Follett J, Rae J, et al. An inverted CAV1 (caveolin 1) topology defines novel autophagy-dependent exosome secretion from prostate cancer cells. Autophagy. 2021;17(9):2200–16.PubMedCrossRef
59.
Gould ML. The intertwining roles of caveolin, oxytocin receptor, and the associated signalling pathways in prostate cancer progression. Reprod Fertil Dev. 2023;35(9):493–503.PubMedCrossRef
60.
Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res. 2001;61(10):3882–5.PubMed
61.
Aliyari M, Elieh Ali Komi D, Kiani A, Moradi M, Tanhapour M, Rahimi Z, et al. The role of caveolin-1 and endothelial nitric oxide synthase polymorphisms in susceptibility to prostate cancer. Int J Exp Pathol. 2021;102(6):260–7.PubMedPubMedCentralCrossRef
62.
Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, et al. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int. 2018;121(1):69–76.PubMedCrossRef
63.
Gumulec J, Sochor J, Hlavna M, Sztalmachova M, Krizkova S, Babula P, et al. Caveolin-1 as a potential high-risk prostate cancer biomarker. Oncol Rep. 2012;27(3):831–41.PubMed
64.
Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate. 2007;67(6):614–22.PubMedCrossRef
65.
Di Vizio D, Morello M, Sotgia F, Pestell RG, Freeman MR, Lisanti MP. An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle. 2009;8(15):2420–4.PubMedCrossRef
66.
Steiner I, Jung K, Miller K, Stephan C, Erbersdobler A. Expression of endothelial factors in prostate cancer: a possible role of caveolin-1 for tumour progression. Oncol Rep. 2012;27(2):389–95.PubMed
67.
Yang G, Timme TL, Frolov A, Wheeler TM, Thompson TC. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer. 2005;103(6):1186–94.PubMedCrossRef
68.
Hammarsten P, Dahl Scherdin T, Hagglof C, Andersson P, Wikstrom P, Stattin P, et al. High Caveolin-1 expression in tumor stroma is associated with a favourable outcome in prostate cancer patients managed by watchful waiting. PLoS ONE. 2016;11(10): e0164016.PubMedPubMedCentralCrossRef
69.
Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 1999;59(22):5719–23.PubMed
70.
Mathieu R, Klatte T, Lucca I, Mbeutcha A, Seitz C, Karakiewicz PI, et al. Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. BJU Int. 2016;118(2):243–9.PubMedCrossRef
71.
Shephard AP, Giles P, Mbengue M, Alraies A, Spary LK, Kynaston H, et al. Stroma-derived extracellular vesicle mRNA signatures inform histological nature of prostate cancer. J Extracell Vesicles. 2021;10(12): e12150.PubMedPubMedCentralCrossRef
72.
Sugie S, Mukai S, Yamasaki K, Kamibeppu T, Tsukino H, Kamoto T. Significant association of Caveolin-1 and Caveolin-2 with prostate cancer progression. Cancer Genom Proteom. 2015;12(6):391–6.
73.
Skara L, Vodopic T, Pezelj I, Abramovic I, Vrhovec B, Vrtaric A, et al. Methylation pattern of caveolin-1 in prostate cancer as potential cfDNA biomarker. Biomol Biomed. 2023;23(1):176–86.PubMedPubMedCentral
74.
Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP, et al. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res. 2006;12(16):4872–5.PubMedCrossRef
75.
Sugie S, Mukai S, Tsukino H, Toda Y, Yamauchi T, Nishikata I, et al. Increased plasma caveolin-1 levels are associated with progression of prostate cancer among Japanese men. Anticancer Res. 2013;33(5):1893–7.PubMed
76.
Yang B, Etheridge T, McCormick J, Schultz A, Khemees TA, Damaschke N, et al. Validation of an epigenetic field of susceptibility to detect significant prostate cancer from non-tumor biopsies. Clin Epigenetics. 2019;11(1):168.PubMedPubMedCentralCrossRef
77.
Yang G, Addai J, Ittmann M, Wheeler TM, Thompson TC. Elevated caveolin-1 levels in African-American versus white-American prostate cancer. Clin Cancer Res. 2000;6(9):3430–3.PubMed
78.
Yang G, Park S, Cao G, Goltsov A, Ren C, Truong LD, et al. MMTV promoter-regulated caveolin-1 overexpression yields defective parenchymal epithelia in multiple exocrine organs of transgenic mice. Exp Mol Pathol. 2010;89(1):9–19.PubMedCrossRef
79.
Bryant KG, Camacho J, Jasmin JF, Wang C, Addya S, Casimiro MC, et al. Caveolin-1 overexpression enhances androgen-dependent growth and proliferation in the mouse prostate. Int J Biochem Cell Biol. 2011;43(9):1318–29.PubMedCrossRef
80.
Zhang X, Ling MT, Wang Q, Lau CK, Leung SCL, Lee TK, et al. Identification of a novel inhibitor of differentiation-1 (ID-1) binding partner, caveolin-1, and its role in epithelial-mesenchymal transition and resistance to apoptosis in prostate cancer cells. J Biol Chem. 2007;282(46):33284–94.PubMedCrossRef
81.
Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, et al. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res. 2001;61(11):4386–92.PubMed
82.
Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C, et al. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med. 1998;4(9):1062–4.PubMedCrossRef
83.
Daniel EE, El-Yazbi A, Cho WJ. Caveolae and calcium handling, a review and a hypothesis. J Cell Mol Med. 2006;10(2):529–44.PubMedCrossRef
84.
Parton RG, Hanzal-Bayer M, Hancock JF. Biogenesis of caveolae: a structural model for caveolin-induced domain formation. J Cell Sci. 2006;119(Pt 5):787–96.PubMedCrossRef
85.
Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacol Rev. 2002;54(3):431–67.PubMedCrossRef
86.
Couet J, Belanger MM, Roussel E, Drolet MC. Cell biology of caveolae and caveolin. Adv Drug Deliv Rev. 2001;49(3):223–35.PubMedCrossRef
87.
Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol. 1998;14:59–88.PubMedCrossRef
88.
Yamamoto H, Komekado H, Kikuchi A. Caveolin is necessary for Wnt-3a-dependent internalization of LRP6 and accumulation of beta-catenin. Dev Cell. 2006;11(2):213–23.PubMedCrossRef
89.
Tahir SA, Yang G, Goltsov A, Song KD, Ren C, Wang J, et al. Caveolin-1-LRP6 signaling module stimulates aerobic glycolysis in prostate cancer. Cancer Res. 2013;73(6):1900–11.PubMedPubMedCentralCrossRef
90.
Rupert JE, Kolonin MG. Fatty acid translocase: a culprit of lipid metabolism dysfunction in disease. Immunometabolism. 2022;4(3): e00001.PubMedCrossRef
91.
Smart EJ, Graf GA, McNiven MA, Sessa WC, Engelman JA, Scherer PE, et al. Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol. 1999;19(11):7289–304.PubMedPubMedCentralCrossRef
92.
Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2(10):795–803.PubMedCrossRef
93.
94.
Michell BJ, Chen Z, Tiganis T, Stapleton D, Katsis F, Power DA, et al. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem. 2001;276(21):17625–8.PubMedCrossRef
95.
Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol. 2003;23(24):9389–404.PubMedPubMedCentralCrossRef
96.
Gao W, Wang Y, Yu S, Wang Z, Ma T, Chan AM, et al. Endothelial nitric oxide synthase (eNOS)-NO signaling axis functions to promote the growth of prostate cancer stem-like cells. Stem Cell Res Ther. 2022;13(1):188.PubMedPubMedCentralCrossRef
97.
Fernandez-Real JM, Catalan V, Moreno-Navarrete JM, Gomez-Ambrosi J, Ortega FJ, Rodriguez-Hermosa JI, et al. Study of caveolin-1 gene expression in whole adipose tissue and its subfractions and during differentiation of human adipocytes. Nutr Metab. 2010;7:20.CrossRef
98.
Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011;30(13):2719–33.PubMedPubMedCentralCrossRef
99.
Moon JS, Jin WJ, Kwak JH, Kim HJ, Yun MJ, Kim JW, et al. Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells. Biochem J. 2011;433(1):225–33.PubMedCrossRef
100.
Maier T, Jenni S, Ban N. Architecture of mammalian fatty acid synthase at 4.5 a resolution. Science. 2006;311(5765):1258–62.PubMedCrossRef
101.
Di Vizio D, Adam RM, Kim J, Kim R, Sotgia F, Williams T, et al. Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase. Cell Cycle. 2008;7(14):2257–67.PubMedCrossRef
102.
Karantanos T, Karanika S, Wang J, Yang G, Dobashi M, Park S, et al. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget. 2016;7(29):46321–34.PubMedPubMedCentralCrossRef
103.
Niaudet C, Bonnaud S, Guillonneau M, Gouard S, Gaugler MH, Dutoit S, et al. Plasma membrane reorganization links acid sphingomyelinase/ceramide to p38 MAPK pathways in endothelial cells apoptosis. Cell Signal. 2017;33:10–21.PubMedCrossRef
104.
Haimovitz-Friedman A, Kan CC, Ehleiter D, Persaud RS, McLoughlin M, Fuks Z, et al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med. 1994;180(2):525–35.PubMedCrossRef
105.
Ketteler J, Wittka A, Leonetti D, Roy VV, Estephan H, Maier P, et al. Caveolin-1 regulates the ASMase/ceramide-mediated radiation response of endothelial cells in the context of tumor-stroma interactions. Cell Death Dis. 2020;11(4):228.PubMedPubMedCentralCrossRef
106.
Pouget JP, Georgakilas AG, Ravanat JL. Targeted and off-target (Bystander and Abscopal) effects of radiation therapy: redox mechanisms and risk/benefit analysis. Antioxid Redox Signal. 2018;29(15):1447–87.PubMedPubMedCentralCrossRef
107.
108.
Corre I, Paris F, Huot J. The p38 pathway, a major pleiotropic cascade that transduces stress and metastatic signals in endothelial cells. Oncotarget. 2017;8(33):55684–714.PubMedPubMedCentralCrossRef
109.
Aberg M, Eden D, Siegbahn A. Activation of beta1 integrins and caveolin-1 by TF/FVIIa promotes IGF-1R signaling and cell survival. Apoptosis. 2020;25(7–8):519–34.PubMedPubMedCentralCrossRef
110.
111.
Huo H, Guo X, Hong S, Jiang M, Liu X, Liao K. Lipid rafts/caveolae are essential for insulin-like growth factor-1 receptor signaling during 3T3-L1 preadipocyte differentiation induction. J Biol Chem. 2003;278(13):11561–9.PubMedCrossRef
112.
113.
Wang Y, Wu X, Ou L, Yang X, Wang X, Tang M, et al. PLCepsilon knockdown inhibits prostate cancer cell proliferation via suppression of Notch signalling and nuclear translocation of the androgen receptor. Cancer Lett. 2015;362(1):61–9.PubMedCrossRef
114.
Jiang J, Eliaz I, Sliva D. Suppression of growth and invasive behavior of human prostate cancer cells by ProstaCaid: mechanism of activity. Int J Oncol. 2011;38(6):1675–82.PubMed
115.
Tahir SA, Kurosaka S, Tanimoto R, Goltsov AA, Park S, Thompson TC. Serum caveolin-1, a biomarker of drug response and therapeutic target in prostate cancer models. Cancer Biol Ther. 2013;14(2):117–26.PubMedPubMedCentralCrossRef
116.
Li-Weber M. New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat Rev. 2009;35(1):57–68.PubMedCrossRef
117.
Wang L, Ling Y, Chen Y, Li CL, Feng F, You QD, et al. Flavonoid baicalein suppresses adhesion, migration and invasion of MDA-MB-231 human breast cancer cells. Cancer Lett. 2010;297(1):42–8.PubMedCrossRef
118.
Bonham M, Posakony J, Coleman I, Montgomery B, Simon J, Nelson PS. Characterization of chemical constituents in Scutellaria baicalensis with antiandrogenic and growth-inhibitory activities toward prostate carcinoma. Clin Cancer Res. 2005;11(10):3905–14.PubMedCrossRef
119.
Kim JK, Jung Y, Wang J, Joseph J, Mishra A, Hill EE, et al. TBK1 regulates prostate cancer dormancy through mTOR inhibition. Neoplasia. 2013;15(9):1064–74.PubMedPubMedCentralCrossRef
120.
121.
Murata M, Peranen J, Schreiner R, Wieland F, Kurzchalia TV, Simons K. VIP21/caveolin is a cholesterol-binding protein. Proc Natl Acad Sci U S A. 1995;92(22):10339–43.PubMedPubMedCentralCrossRef
122.
Hong H, Zhang Y, Sun J, Cai W. Positron emission tomography imaging of prostate cancer. Amino Acids. 2010;39(1):11–27.PubMedCrossRef
123.
Jia L, Wei W, Cao J, Xu H, Miao X, Zhang J. Silencing CD147 inhibits tumor progression and increases chemosensitivity in murine lymphoid neoplasm P388D1 cells. Ann Hematol. 2009;88(8):753–60.PubMedCrossRef
124.
Langeberg WJ, Tahir SA, Feng Z, Kwon EM, Ostrander EA, Thompson TC, et al. Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. Prostate. 2010;70(9):1020–35.PubMedPubMedCentralCrossRef
125.
Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N- (2-chloro-6-methyl- phenyl)-2- (6- (4- (2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47(27):6658–61.PubMedCrossRef
126.
Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005;65(20):9185–9.PubMedCrossRef
127.
Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327–37.PubMed
128.
Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007;6(9):734–45.PubMedCrossRef
129.
Carducci MA, Nelson JB, Chan-Tack KM, Ayyagari SR, Sweatt WH, Campbell PA, et al. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res. 1996;2(2):379–87.PubMed
130.
Melchior SW, Brown LG, Figg WD, Quinn JE, Santucci RA, Brunner J, et al. Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo. Int J Oncol. 1999;14(3):501–8.PubMed
Metadata
Title
Molecular pathogenesis, mechanism and therapy of Cav1 in prostate cancer
Authors
Qiang Bian
Bei Li
Luting Zhang
Yinuo Sun
Zhankui Zhao
Yi Ding
Honglian Yu
Publication date
01-12-2023
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-023-00813-0

Other articles of this Issue 1/2023

Discover Oncology 1/2023 Go to the issue

Research

A modified melanoma-molGPA scoring model: assessment of survival after and efficacy of different radiotherapy modalities in patients with melanoma brain metastases

Perspective

Environmental insults and compensative responses: when microbiome meets cancer

Research

ARAP1 negatively regulates stress fibers formation and metastasis in lung adenocarcinoma via controlling Rho signaling

Research

A novel PD-1/PD-L1 pathway molecular typing-related signature for predicting prognosis and the tumor microenvironment in breast cancer

Research

AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research

Research

TOM40 regulates the progression of nasopharyngeal carcinoma through ROS-mediated AKT/mTOR and p53 signaling
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits